Senzime AB Asset Resilience Ratio

Latest as of December 2025: 20.00%

Senzime AB asset resilience ratio. Senzime AB (SEZI) has an Asset Resilience Ratio of 20.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See defensive interval ratio of Senzime AB to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr73.97 Million
≈ $7.96 Million USD Cash + Short-term Investments

Total Assets

Skr369.81 Million
≈ $39.80 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Senzime AB (2016–2025)

Asset resilience ratio of Senzime AB from 2016 to 2025. This chart shows how Senzime AB's Asset Resilience Ratio has changed over time. Read SEZI total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Senzime AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Senzime AB (SEZI) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr73.97 Million 20.0%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr73.97 Million 20.00%

Asset Resilience Insights

  • Good Liquidity Position: Senzime AB maintains a healthy 20.00% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Senzime AB Industry Peers by Asset Resilience Ratio

Compare Senzime AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
HOB Biotech Group Corp Ltd
SHG:688656
Medical Devices 2.62%
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
Applied BioCode
TW:6598
Medical Devices 9.75%
Oncosil Medical Ltd
AU:OSL
Medical Devices 0.00%
Cleo Diagnostics Ltd
AU:COV
Medical Devices 94.64%
Radiant Innovation
TWO:3373
Medical Devices 0.82%
Impedimed Ltd
AU:IPD
Medical Devices 46.15%
Memphasys Ltd
AU:MEM
Medical Devices 0.00%

Senzime AB Asset Resilience Ratio by Year (2016–2025)

Senzime AB asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Senzime AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 20.00% Skr73.97 Million
≈ $7.96 Million
Skr369.81 Million
≈ $39.80 Million
-3.67pp
2024-12-31 23.67% Skr100.94 Million
≈ $10.86 Million
Skr426.36 Million
≈ $45.88 Million
-11.16pp
2023-12-31 34.83% Skr151.01 Million
≈ $16.25 Million
Skr433.54 Million
≈ $46.66 Million
+26.76pp
2022-12-31 8.07% Skr26.04 Million
≈ $2.80 Million
Skr322.68 Million
≈ $34.73 Million
-34.81pp
2021-12-31 42.88% Skr74.87 Million
≈ $8.06 Million
Skr174.62 Million
≈ $18.79 Million
-19.04pp
2020-12-31 61.92% Skr160.31 Million
≈ $17.25 Million
Skr258.89 Million
≈ $27.86 Million
+45.47pp
2019-12-31 16.46% Skr30.90 Million
≈ $3.33 Million
Skr187.76 Million
≈ $20.21 Million
-0.11pp
2018-12-31 16.57% Skr32.67 Million
≈ $3.52 Million
Skr197.16 Million
≈ $21.22 Million
+11.31pp
2017-12-31 5.26% Skr8.74 Million
≈ $940.35K
Skr166.03 Million
≈ $17.87 Million
-1.15pp
2016-12-31 6.41% Skr10.03 Million
≈ $1.08 Million
Skr156.31 Million
≈ $16.82 Million
--
pp = percentage points

About Senzime AB

ST:SEZI Sweden Medical Devices
Market Cap
$54.99 Million
Skr510.95 Million SEK
Market Cap Rank
#21351 Global
#390 in Sweden
Share Price
Skr3.25
Change (1 day)
+3.83%
52-Week Range
Skr2.42 - Skr5.81
All Time High
Skr26.50
About

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. The company offers TetraGraph, quantitative train of-four (TOF) monitoring refined by real-world patient data; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impeda… Read more